Frazier Life Sciences Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Frazier Life Sciences Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,345,559	Closed	-$167M	–	56
2023 Q2	$167M	Hold	4,345,559	–	–	9.97%	2
2023 Q1	$101M	Hold	4,345,559	–	–	7.28%	3
2022 Q4	$114M	Buy	4,345,559 +80,000	+2%	+$1.77M	7.08%	4
2022 Q3	$83.9M	Buy	4,265,559 +670,533	+19%	+$13.4M	6.46%	4
2022 Q2	$62.9M	Buy	3,595,026 +882,985	+33%	+$13.9M	5.93%	5
2022 Q1	$44.4M	Buy	+2,712,041	New	+$36.9M	3.78%	9

Frazier Life Sciences Management's KDNY Position: Q3 2023 in Review

Frazier Life Sciences Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 4,345,559 shares — an estimated $167M sold.

Frazier Life Sciences Management first reported a position in KDNY in Q1 2022 and held it in 6 quarters. The position peaked at $167M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Frazier Life Sciences Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Frazier Life Sciences Management sold 4,345,559 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $167M.
Frazier Life Sciences Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Frazier Life Sciences Management's Chinook Therapeutics, Inc. Common Stock position peaked at $167M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.